Coeptis Therapeutics Holdings Inc
COEP14.640USD
-0.110-0.75%
Fechamento 11/05, 16:00（ET）Cotações atrasadas em 15 min
61.00MValor de mercado
PerdaP/L TTM
Mais detalhes de Coeptis Therapeutics Holdings Inc Empresa
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Informações de Coeptis Therapeutics Holdings Inc
Código da empresaCOEP
Nome da EmpresaCoeptis Therapeutics Holdings Inc
Data de listagemDec 17, 2020
CEO- -
Número de funcionários5
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 17
Endereço105 Bradford Road, Suite 420
CidadeWEXFORD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal15090
Telefone17249346467
Sitehttps://coeptistx.com/
Código da empresaCOEP
Data de listagemDec 17, 2020
CEO- -
Executivos da empresa Coeptis Therapeutics Holdings Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Outro
86.86%
Investidores
Investidores
Proporção
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Outro
86.86%
Tipos de investidores
Investidores
Proporção
Individual Investor
11.27%
Corporation
2.13%
Hedge Fund
1.97%
Investment Advisor
0.64%
Investment Advisor/Hedge Fund
0.42%
Outro
83.58%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
31
146.21K
3.03%
+12.13K
2025Q2
42
850.21K
24.20%
+80.97K
2025Q1
44
802.79K
23.54%
+88.77K
2024Q4
46
470.87K
21.82%
-146.34K
2024Q3
60
665.36K
32.36%
-151.44K
2024Q2
63
660.64K
38.75%
-415.23K
2024Q1
86
813.98K
47.41%
-385.62K
2023Q4
86
964.24K
63.23%
-125.48K
2023Q3
87
697.73K
55.24%
-487.79K
2023Q2
87
705.35K
60.53%
-350.78K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Calise (Chris)
312.69K
6.49%
--
--
Sep 11, 2025
Mehalick (David)
130.07K
2.7%
--
--
Sep 11, 2025
Armistice Capital LLC
94.77K
1.97%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
1.05%
--
--
Sep 11, 2025
Yerace (Daniel Alexander)
45.53K
0.94%
-5.00K
-9.89%
Sep 11, 2025
The Vanguard Group, Inc.
27.53K
0.57%
+3.09K
+12.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
20.28K
0.42%
+311.00
+1.56%
Jun 30, 2025
Salkind (Gene)
4.21K
0.09%
--
--
Sep 11, 2025
Sea Otter Advisors LLC
2.25K
0.05%
--
--
Jun 30, 2024
Steward Partners Investment Advisory, LLC
1.00K
0.02%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Data
Tipo
Proporção
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
